These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37638400)

  • 21. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 22. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
    Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
    Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.
    Ford JH; Ye W; Ayer DW; Mi X; Bhandari S; Buse DC; Lipton RB
    J Patient Rep Outcomes; 2023 Apr; 7(1):34. PubMed ID: 37016181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Pozo-Rosich P; Ailani J; Ashina M; Goadsby PJ; Lipton RB; Reuter U; Guo H; Schwefel B; Lu K; Boinpally R; Miceli R; De Abreu Ferreira R; McCusker E; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Sep; 402(10404):775-785. PubMed ID: 37516125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis.
    Hou M; Luo X; He S; Yang X; Zhang Q; Jin M; Zhang P; Li Y; Bi X; Li J; Cheng C; Xue Q; Xing H; Liu Y
    J Headache Pain; 2024 Jul; 25(1):116. PubMed ID: 39030528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
    Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Speck RM; Yu R; Ford JH; Ayer DW; Bhandari R; Wyrwich KW
    Headache; 2021 Mar; 61(3):511-526. PubMed ID: 33481276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
    Klein BC; Miceli R; Severt L; McAllister P; Mechtler L; McVige J; Diamond M; Marmura MJ; Guo H; Finnegan M; Trugman JM
    Cephalalgia; 2023 Jan; 43(1):3331024221128250. PubMed ID: 36620892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
    Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of migraine on daily activities: effect of topiramate compared with placebo.
    Silberstein SD; Loder E; Forde G; Papadopoulos G; Fairclough D; Greenberg S
    Curr Med Res Opin; 2006 Jun; 22(6):1021-9. PubMed ID: 16846536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
    Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.